Dr Patricia Steeg speaks to ecancer at SABCS 2018 about the how brain metastases can develop from metastatic HER2 positive and triple negative breast cancer.

She reports that a mouse model has been used in order to find a drug that can prevent brain metastases from being developed from these subtypes, with the drug temozolomide showing significant capabilities of prevention.

Dr Steeg explains that a secondary metastases prevention trial has been set up with HER2 positive breast cancer patients who already have signs of brain metastases, with a primary endpoint of no additional brain metastases.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php